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ABSTRACT
Introduction: The aim of this study was to evaluate the expression of PD-L1 
in oropharyngeal squamous cell carcinoma. Its relation with clinicopathological 
variables, tumor infiltrating lymphocytes and survival was also determined.
Results: Positive PD-L1 status for the SP142 clone related with improved overall 
survival in oropharyngeal squamous cell carcinoma. Tumors heavily infiltrated by 
tumor infiltrating lymphocytes were also linked with better outcome, and this as 
well for the total number of tumor infiltrating lymphocytes as for the CD3+ and CD8+ 
T cell count. A Cox proportional hazard model proved that solely infiltrating CD8+ T 
cells exhibit a positive effect on overall survival (hazard ratio = 0.31 [0.14–0.70];  
P = 0.0050)
Materials and Methods: Formalin-fixed, paraffin-embedded tissue from 
oropharyngeal tumors of 99 patients was immunohistochemically stained for PD-L1 
(SP142 and 22C3 clones), CD3, CD8 and FoxP3. Expression of PD-L1, CD3, CD8, FoxP3 
and HPV status were correlated with clinicopathological variables. Overall survival 
was determined by a log-rank (Mantel–Cox) test whereas the Cox proportional hazard 
model was used for multivariate analysis.
Conclusions: Our results demonstrate that CD8+ T lymphocytes constitute an 
independent prognostic marker in patients diagnosed with oropharyngeal squamous 
cell carcinoma. PD-L1 positivity for SP142, but not for 22C3, also tends to have a 
positive effect on survival in oropharyngeal squamous cell carcinoma.
INTRODUCTION
Over the last decades there has been an increase in 
oropharyngeal squamous cell carcinoma (OSCC) which 
has mainly been attributed to human papillomavirus 
(HPV) infection [1, 2]. HPV-associated OSCC seems 
to be a distinct clinical entity, compared to tobacco 
related squamous cell carcinoma of the head and neck 
(SCCHN): patients (1) tend to be younger, (2) lack a 
history of smoking and/or alcohol abuse and (3) have a 
significant survival benefit [1, 3–9]. These observations 
have raised the possibility that some of these patients 
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receive unnecessary treatment and are therefore exposed 
to unnecessary toxicity. Refining patient stratification by 
considering additional biomarkers next to HPV status may 
ensure appropriate therapy and therefore better survival 
and improved quality of life.
Programmed cell death protein 1 (PD-1) is a 50-55 
kDa type I transmembrane receptor expressed by activated 
T and B cells, as well as by monocytes and dendritic cells. It 
has two binding partners, PD-L1 and PD-L2, each specific 
for various tissue types and with specific expression 
patterns. PD-L1 is expressed on immune cells (ICs) 
including T cells, dendritic cells and monocytes. In addition, 
PD-L1 is expressed in the context of T cell exhaustion 
during chronic viral infection (e.g. HPV infection) and by 
tumor cells (TCs) [10–12]. The presence of PD-L1 on TCs 
contributes to the process of immune evasion [13], hence 
PD-L1 expression is confirmed to be a marker of poor 
prognosis in the majority of solid tumors [14]. In the context 
of SCCHN (including OSCC) there is no consensus yet on 
the role of PD-L1 expression as a prognostic biomarker 
[15–18]. Multiple antibody (Ab) clones are currently 
analyzed for PD-L1 expression on cancer cells and 
in the cancer microenvironment using different 
immunohistochemical staining platforms or in-house 
staining procedures, often yielding different staining 
patterns. Moreover, read-out of PD-L1 positivity can be done 
on TCs as well as on ICs in the tumor microenvironment. 
This methodological complexity only contributes to the 
contradictorily results on the value of PD-L1 as biomarker. 
Therefore, the aim of this study was to perform additional 
research on the role of PD-L1 in SCCHN, focusing only on 
OSCC, using two clones from FDA approved kits, namely 
the 22C3 clone (Agilent-DAKO) and the SP142 clone 
(Roche), and scoring both TCs and ICs. We evaluated the 
expression of PD-L1 in OSCC and looked for associations 
with clinicopathological variables and the amount and type 
of tumor infiltrating lymphocytes (TILs). In addition we 
assessed the effect of PD-L1 status and the tumor immune 
cell infiltrate on outcome.
RESULTS
Patient characteristics
The 99 patients included in this study were 
predominantly male (83%), and represented primarily 
stage III/IV tumors (83%). Most of the tumors originated 
from the tonsil (43%) and were moderately (62%) 
differentiated. The overall HPV prevalence rate was 
19% (19/99) with no difference in distribution along all 
topographic sites (P = 0.5673). More HPV+ specimens 
were detected among poorly differentiated and basaloid 
tumors (11/32) compared to well/moderately differentiated 
tumors (8/67; P = 0.0265).
Patients clinicopathological variables are displayed 
in Table 1.
The pattern of PD-L1 expression 
Tumor cells (TCs)
Using the SP142 clone for evaluation of PD-L1 
expression, PD-L1 status of TCs was categorized as 
follows: IHC 0 (58%), IHC 1 (15%), IHC 2 (12%) and 
IHC 3 (10%). Five samples (5%) could not be evaluated. 
Using the 22C3 clone, distribution of tumoral IHC 
scores was as follows: IHC 0 (45%), IHC 1 (20%), IHC 
2 (13%) and IHC 3 (20%). Two samples (2%) could not 
be evaluated. PD-L1 positivity defined as ≥ 5% PD-L1 
expression on TCs resulted in 23% (22/94) and 34% 
(33/97) PD-L1+ tumor specimens for the SP142 and 22C3 
clone, respectively (Table 1).
Immune cells (ICs)
Only little tumor infiltrating ICs expressed PD-L1 
(SP142 clone) with IHC 0 in 76 cases (77%), IHC 1 in 9 
cases (9%), IHC 2 in one case (1%) and IHC 3 in one case 
(1%). Twelve samples (12%) were not evaluable. Similar 
to the SP142 clone, low expression was observed on ICs 
for the 22C3 clone: IHC 0 in 66% of cases, IHC 1 in 16% 
of cases, IHC 2 in 3% of cases and no IHC 3. Thirteen 
samples could not be evaluated. 
Relation of PD-L1 expression on TCs with 
different clinicopathological variables 
A positive link was found between HPV status and 
PD-L1 positivity on TCs for the SP142 clone (P < 0.0001) 
and 22C3 clone (P = 0.0649). Next, positive SP142 PD-
L1 expression was associated with poorly differentiated/
basaloid tumors (15/29 versus 7/65; P = 0.0001) whereas 
positive 22C3 PD-L1 expression on TCs was most 
common in elder patients (8/12 versus 25/85; P = 0.0234) 
and in poorly differentiated/basaloid tumors (17/31 versus 
16/66; P = 0.0111).
All associations between PD-L1 on TCs and 
clinicopathological variables are presented in Table 1.
Relation of PD-L1 expression on TCs with TILs 
Notably, PD-L1 positivity on TCs was linked with 
the immune environment, as this parameter was associated 
with increased TIL count (P < 0.0001 and P = 0.0009), 
CD3+ T cell count (P = 0.0009 and P = 0.0044), CD8+ 
T cell count (P < 0.0001 and P = 0.0001) and FoxP3+ T 
cell count (P = 0.0004 and P = 0.0094) for the SP142 and 
22C3 clone, respectively. 
All associations with TILs are given in Table 2.
Relation of PD-L1 expression on TCs with 
clinical outcome 
Positive PD-L1 expression using the SP142 clone 
resulted in a more favorable outcome with median overall 
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survival (OS) of 9.8 years versus 4.1 years for SP142 PD-
L1 negativity (hazard ratio [HR] = 0.51 [0.31–0.99], P = 
0.0466; Figure 1A) whereas 22C3 PD-L1 expression on 
TCs showed no significant association with OS (4.0 years 
versus 4.4 years; HR = 0.99 [0.58–1.72], P = 0.9846; 
Figure 1B). None of the PD-L1 markers was associated 
with prolonged disease-free survival (DFS) (HR SP142 
= 0.43 [0.22–1.16], P = 0.1070 and HR 22C3 = 1.28 
[0.60–2.83], P = 0.5110; Figure 1C–1D). An overview 
of the HRs on DFS for all tumor markers, IC markers 
and associated clinicopathological markers is given in 
Supplementary Table 1.
The relation between TILs and outcome was evaluated 
as well. High TIL count, high CD3+ T cell count and high 
Table 1: Association between PD-L1 on tumor cells, CD8+ T cells and clinicopathological variables
Parameter
Overall SP142 PD-L1 22C3 PD-L1 CD8+ T cell count
Negative Positive P-value Negative Positive P-value Low High P-value
Patient number 99 (100) 72 (77) 22 (23) 64 (66) 33 (34) 67 (77) 20 (23)
Age        
 < 50 years 13 (13) 11 (11) 1 (1)
0.1522*
10 (10) 2 (2)
0.0234*
8 (9) 1 (1)
0.0248* 50–69 years 74 (75) 54 (57) 16 (17) 50 (52) 23 (24) 54 (62) 13 (15)
 ≥ 70 years 12 (12) 7 (7) 5 (5) 4 (4) 8 (9) 5 (6) 6 (7)
Gender        
 Female 17 (17) 12 (13) 5 (5)
0.5351
12 (13) 5 (5)
0.7820
14 (16) 3 (3)
0.7515
 Male 82 (83) 60 (64) 17 (18) 52 (54) 28 (29) 53 (61) 17 (20)
Tumor site        
 Tonsil 43 (43) 29 (31) 13 (14)
0.2108*
23 (24) 20 (21)
0.1621*
28 (32) 10 (12)
0.1330* Tongue base 12 (12) 5 (5) 5 (5) 6 (6) 5 (5) 5 (6) 4 (5)
 Other sites 23 (23) 17 (18) 4 (4) 17 (18) 5 (5) 17 (20) 2 (2)
 Multiple subsites 21 (21) 21 (22) 0 (0) 18 (19) 3 (5) – 17 (20) 4 (5) –
T stage        
 T1-2 56 (57) 39 (42) 16 (17) 0.1441
32 (33) 23 (24)
0.0650*
32 (37) 17 (20)
0.0041
 T3-4 43 (43) 33 (35) 6 (6) 32 (33) 10 (10) 35 (40) 3 (3)
N stage        
 N0 30 (30) 23 (25) 4 (4)
0.2100*
21 (22) 8 (8)
0.0939*
19 (22) 5 (6)
0.6038* N1 14 (14) 12 (13) 2 (2) 12 (12) 2 (2) 12 (14) 2 (2)
 N2-3 55 (56) 37 (39) 16 (17) 31 (32) 23 (24) 36 (41) 13 (15)
Prognostic stage        
 I/II 17 (17) 15 (16) 2 (2)
0.3430
12 (13) 5 (5)
0.7820
10 (12) 4 (5)
0.7291
 III/IV 82 (83) 57 (61) 20 (21) 52 (54) 28 (29) 57 (66) 16 (18)
Grade of 
differentiation        
 Well/moderately 67 (68) 58 (62) 7 (7)
0.0001*
50 (52) 16 (17)
0.0111*
52 (60) 8 (9)
0.0006* Poorly 19 (19) 8 (8) 10 (10) 8 (8) 11 (11) 6 (7) 9 (10)
 Basaloid 13 (13) 6 (6) 5 (5) 6 (6) 6 (6) 9 (10) 3 (3)
HPV status        
 Negative 80 (81) 66 (70) 11 (12)
< 0.0001
55 (57) 23 (24)
0.0649
57 (66) 13 (15)
0.0591
 Positive 19 (19) 6 (6) 11 (12) 9 (9) 10 (10) 10 (12) 7 (8)
Primary therapy        
 Surgery 51 (52) 34 (36) 15 (16)
0.1374*
31 (31) 19 (20)
0.4390*
32 (37) 11 (13)
0.0521* Radiotherapy 25 (25) 18 (19) 5 (5) 16 (17) 9 (9) 15 (17) 8 (9)
 Chemoradiotherapy 23 (23) 20 (21) 2 (2) 17 (18) 5 (5) 20 (23) 1 (1)
Data given are numbers, percentages are given between brackets (%). Overall column displays total numbers (%). Cut-off values 
were taken at median values (3+: abundant occurrence of  CD8+ T cells) and at ≥ 5% for PD-L1 on TCs (SP142 clone and 22C3 
clone). Samples that were classified as ‘impossible to evaluate’ were not included in the analysis. P-value calculated by Fisher 
exact test unless otherwise indicated (*P-value calculated by Chi-square test). HPV, human papillomavirus.
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CD8+ T cell count but not FoxP3+ T cell count proved to 
have a favorable influence on OS (Supplementary Figure 1). 
Particularly, an elevated CD8+ T cell count was significantly 
associated with prolonged OS (9.8 years) versus patients with 
a low CD8+ T cell count (3.5 years; HR = 0.32 [0.22–0.71], P 
= 0.0020). As CD8+ T cell count proved the strongest marker 
of the immune cell infiltrate, an analysis was performed 
combining CD8+ T cell count and PD-L1 expression on TCs. 
The combined analysis of SP142 PD-L1 expression on TCs 
and CD8+ T cell count showed that this combination was 
significantly correlated with OS: median OS of 9.8 years, 
not reached, 2.4 years and 4.0 years for the PD-L1+/high 
CD8+, PD-L1–/high CD8+, PD-L1+/low CD8+, and PD-L1–/
low CD8+ cohorts, respectively (P = 0.0321; Figure 2A). 
Similar, a significance was found for combining 22C3 PD-
L1 expression on TCs and CD8+ T cell count with median 
OS of 9.8 years, not reached, 2.1 years and 4.1 years for the 
respective cohorts (P = 0.0118; Figure 2B). As the majority 
of patients were stratified as PD-L1–/low CD8+, patients were 
bicategorically categorized as ‘at least one variable positive’ 
versus PD-L1–/low CD8+. Patients with ‘at least one variable 
positive’ had a more favorable outcome for the SP142 PD-L1 
expression (median OS 9.8 years versus 4.0 years; HR = 0.40 
[0.24–0.78], P = 0.0048; Figure 2C) but not for the 22C3 
PD-L1 expression (median OS 5.5 years versus 4.1 years; 
HR = 0.66 [0.38–1.15], P = 0.1415; Figure 2D).
In the multivariate model, which adjusted for HPV 
status, CD8+ T cell count proved to be the independent 
prognosticator for OS (HR = 0.31 [0.14–0.70]; 
P = 0.0050) whereas SP142 PD-L1 positivity and other 
immune cell counts did not contribute to the model. When 
assessing the combination of SP142 PD-L1 expression and 
CD8+ T cell count in the multivariate model, patients with 
'at least one variable positive' had an OS benefit compared 
with PD-L1-/low CD8+ patients (HR = 0.39 [0.20–0.78]; 
P = 0.0070).
Table 2: Association between PD-L1 on tumor cells and stromal immune cell infiltrate
Parameter
Overall SP142 PD-L1 22C3 PD-L1
Negative Positive P-value Negative Positive P-value
Patient number 99 (100) 72 (77) 22 (23) 64 (66) 33 (34)
TIL count
 1+ 12 (12) 12 (14) 0 (0)
< 0.0001
11 (12) 1 (1)
0.0009
 2+ 42 (42) 37 (42) 3 (3) 32 (36) 9 (10)
 3+ 26 (26) 14 (16) 11 (13) 13 (14) 13 (14)
 4+ 11 (11) 4 (5) 7 (8) 3 (3) 8 (9)
 ITE 8 (8)
CD3+ T cell count
 1+ 20 (20) 18 (21) 0 (0)
0.0009
15 (17) 4 (5)
0.0044
 2+ 33 (33) 28 (32) 5 (6) 26 (29) 8 (9)
 3+ 19 (19) 12 (14) 7 (8) 12 (14) 7 (8)
 4+ 17 (17) 8 (9) 9 (10) 5 (6) 12 (14)
 ITE 10 (10)
CD8+ T cell count
 1+ 36 (36) 34 (40) 2 (2)
< 0.0001
30 (35) 7 (8)
0.0001 2+ 31 (31) 24 (28) 5 (6) 22 (25) 8 (9)
 3+ 20 (20) 8 (9) 12 (14) 5 (6) 15 (17)
 ITE 12 (12)
FoxP3+ T cell count
 1+ 58 (59) 51 (59) 7 (8)
0.0004*
44 (49) 15 (17)
0.0094
 2+ 31 (31) 15 (17) 14 (16) 14 (16) 16 (18)
 ITE 10 (10)
Data given are numbers, percentages are given between brackets (%). Cut-off values were taken at ≥ 5% for PD-L1 on TCs 
(SP142 clone and 22C3 clone). Parameters in bold and underlined represent median cut-off values used for survival analysis: 
3+ (TIL count, CD3+ T cell count and CD8+ T cell count) and 2+ (FoxP3+ T cell count). Samples that were classified as 
‘impossible to evaluate’ were not included in the analysis. P-value calculated by Chi-square test unless otherwise indicated (* 
P-value calculated by Fisher exact test). ITE, impossible to evaluate; TIL, tumor-infiltrating lymphocyte.
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An overview of all multivariate HR is given in 
Table 3.
Relation of PD-L1 expression on ICs with 
clinicopathological variables, TILs and clinical 
outcome
No relation was demonstrated between PD-
L1 expression (SP142 or 22C3 clone) on ICs and 
clinicopathological variables, including TILs, overall and 
disease-free survival. 
DISCUSSION
In our study, positive PD-L1 expression on TCs 
using the SP142 clone was noticed in 23% of specimens 
whereas 34% of specimens were PD-L1+ according to the 
22C3 clone (≥ 5 % cut-off). The number of PD-L1+ samples 
is considerably lower in comparison to other previously 
reported data on the expression of PD-L1 in OSCC 
[19, 20]. These differences might be partially explained 
by the difference in sample size. However, the main 
confounder for the lower PD-L1 expression is probably 
the use of different Ab clones. Each Ab targets different 
epitopes of PD-L1 with different affinity, resulting in 
different staining patterns [21]. When considering PD-L1 
as a biomarker in daily clinical practice, one should be 
aware of these methodological concerns and validation 
and quality assessment of this immunohistochemical 
marker will prove to be of the utmost importance. 
The study of PD-L1 expression on ICs did not add 
useful data to our study, probably because of the very low 
expression levels (98% of the samples using the SP142 
clone and 97% of the samples using the 22C3 clone 
[≥ 5% cut-off] were PD-L1–). The expression of PD-L1 on 
tumor infiltrating ICs is well known but further research 
is warranted in order to evaluate its contribution to the 
(anti-) tumor immune response and its link with PD-L1 
expression on TCs. 
We found PD-L1 expression on TCs determined by 
SP142 and 22C3 staining to be positively associated with 
high number of TILs, high CD3+ T cell count, high CD8+ 
T cell count and high FoxP3+ T cell count. These findings 
reflect the hypothesis that a PD-L1 mediated adaptive 
Figure 1: Survival outcome of PD-L1 expression. (A) OS of SP142 PD-L1 (0.51 [0.31–0.99], P = 0.0466); (B) OS of 22C3 PD-L1 
(0.99 [0.58–1.72], P = 0.9846); (C) DFS of SP142 PD-L1 (0.43 [0.22– 1.16], P = 0.1070) and (D) DFS of 22C3 PD-L1 (1.28 [0.60–2.83], 
P = 0.5110). Cut-off values  were taken at ≥ 5% for PD-L1 on TCs (SP142 and 22C3 clone). 
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immune resistance is induced following interferon-
gamma secretion by TILs [22]. It is reported that PD-L1 
expression is visually higher in areas with high T cell 
infiltrate and this finding is confirmed in our study [23]. 
PD-L1 was also associated with positive HPV status 
which in turn was nearly significantly associated with 
CD8+ T cells. As PD-L1 expression is observed in the deep 
invaginations of tonsillar crypts in non-cancerous tonsils 
as well, this observation might suggest that virus induced 
malignant transformation could be enhanced in the 
reticulated epithelium of tonsillar crypts in the presence 
of PD-L1. 
Survival analysis revealed that PD-L1 positivity 
of TCs, using the SP142 clone, was related to better OS 
but not with DFS in univariate analysis. Also high CD8+ 
T cell count showed prognostic OS benefit in OSCC, 
irrespective of the HPV status. As both CD8+ T cell count 
and PD-L1 status were related to a better OS, their effect 
was even more pronounced when using a combined 
prognostic biomarker based on PD-L1 status plus CD8+ T 
cell count. Having ‘at least one variable positive’ resulted 
in an increased survival outcome compared to patients 
who were stratified as PD-L1–/low CD8+. The link of PD-
L1 with T-cell infiltrate and HPV status as demonstrated 
by our own study should at least partially be accounted 
for this observation. The fact that PD-L1+ tumors and 
high infiltration of CD8+ T lymphocytes showed better 
survival outcome might come across as a paradox since 
high CD8+ lymphocyte count indicates an active immune 
response with anti-tumor effect whereas PD-L1 positivity 
is assumed to dampen this response. This observation 
demonstrates that PD-L1 expression cannot be interpreted 
simply as a marker of immune suppression but rather 
reflects a response to (over-) activation of an endogenous 
inflammatory immune response at the tumor site [23, 24].
To our knowledge, this is the first study to evaluate 
the expression of PD-L1 in OSCC using two monoclonal 
Abs (SP142 clone and 22C3 clone) from FDA approved 
kits that are currently used in various clinical trials. 
Pharmacodiagnostic testing for anti-PD-(L)1 therapy 
is nowadays mainly performed with two clones from 
Agilent-DAKO and two clones from Roche. Recently, 
it was reported that staining results for the 22C3 clone 
are in concordance with those obtained from the 28-8 
and SP263 clone, but not with those of the SP142 clone 
[25, 26] and this incited us to focus on the 22C3 and SP142 
clone for this study. Besides, we chose to include tumors 
arising from one primary tumor site. Although SCCHN 
is often considered one entity, recent publications report 
a heterogeneous molecular and immunological tumor 
Table 3: Multivariate Cox regression model for overall survival outcome
Parameter
Separate immune markers Combination of immune markers
Multivariate HR (95% CI) P-value Multivariate HR (95% CI) P-value
HPV status
 Negative 1 1
 Positive 0.55 (0.21–1.43) 0.2213 0.61 (0.25–1.49) 0.2786
TIL count
 Low 1 1
 High 1.06 (0.48–2.35) 0.8828 1.11 (0.49–2.52) 0.7976
CD3+ T cell count
 Low 1 1
 High 0.94 (0.45–1.97) 0.8660 0.77 (0.37–1.61) 0.4859
CD8+ T cell count
 Low 1
 High 0.31 (0.14–0.70) 0.0050
SP142 PD-L1
 Negative 1
 Positive 0.98 (0.35–2.74) 0.9689
Combination SP142 PD-L1/CD8+ T cell count
 PD-L1–/low CD8 + 1
 At least 1 positive/high 0.39 (0.20–0.78) 0.0070
Multivariate HRs were calculated through a Cox proportional-hazards regression model. Multivariate analysis was performed 
for CD8+ T cell count and SP142 PD-L1 as separate immune markers or as combined immune markers. Cut-off values were 
taken at median values (3+: abundant occurrence of  TILs, CD3+ T cells and CD8+ T cells) and at ≥ 5% for PD-L1 on tumor 
cells (SP142 clone). HPV, human papillomavirus; HR, hazard ratio; TIL, tumor-infiltrating lymphocyte.
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profile of these malignancies on different anatomical 
localizations [27, 28]. Therefore it is desirable to focus 
on one tumor site rather than on SCCHN in general and 
thus we restricted the assessment of PD-L1 expression to 
a well-defined population of patients with tumors arising 
from the oropharynx. 
Also, we deliberately chose to work with formalin-
fixed, paraffin-embedded (FFPE) samples from biopsies 
or resections as this is the material that will be available 
for prognostic biomarker testing in the future. Although 
biopsy samples might harbor sampling errors and suffer 
from spatial heterogeneity in PD-L1 expression, it is 
important to include these samples in the trials to avoid 
selection bias. It remains however important to evaluate 
the concordance of PD-L1 expression between different 
available clones, between different cut-off values and 
between samples from different origins (e.g. biopsy versus 
resection specimens). 
In conclusion our results demonstrate that CD8+ 
TILs constitute a strong positive prognostic marker in 
patients diagnosed with OSCC. Furthermore, PD-L1 
expression on TCs, assessed by the SP142 clone, also 
tends to have a positive effect on patient outcome in 
OSCC. The results of this retrospective study should be 
confirmed in prospective trials to assess the clinical impact 
of the biomarkers on routine daily practice. Herein, special 
attention should be given to methodological issues on PD-
L1 testing that were also of concern in this study, such as 
choice of Ab clone, interpretation criteria and sample type. 
MATERIALS AND METHODS
Study population
Ninety-nine patients with histologically proven 
OSCC (anno 2004-2013) were selected from the 
archival database of the Department of Pathology, Ghent 
University Hospital. Patients were excluded from the 
study in case of recurrent or distant metastatic disease. 
When available, samples from resection specimens were 
Figure 2: Overall survival outcome combining PD-L1 expression on tumor cells with CD8+ T cell count. (A) SP142 PD-
L1/CD8+ T cell count: all groups (P = 0.0321); (B) 22C3 PD-L1/CD8+ T cell count: all groups (P = 0.0118); (C) SP142 PD-L1/CD8+ T cell 
count: PD-L1–/low CD8+ versus at least one variable positive (0.40 [0.24–0.78], P = 0.0048) and (D) 22C3 PD-L1/CD8+ T cell count: PD-
L1–/low CD8+ versus at least one variable positive (0.66 [0.38–1.15], P = 0.1415). Cut-off values were taken at median values (3: abundant 
occurrence of  CD8+ T cells) and at ≥ 5% for PD-L1 on tumor cells (SP142 and 22C3 clone). 
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preferred for further analysis (n = 27), if not, endoscopic 
biopsy material was used (n = 72).
The study was approved by the ethics committee of 
the Ghent University Hospital.
Clinical, treatment and follow-up data were 
retrieved from the electronic patient data file. Tumor sites 
consisted of tonsil, tongue base, other (e.g. tonsillar pillars, 
posterior wall, vallecula) or multiple subsites involved. 
The majority of the patients was treated surgically (n = 
51) by either tumor resection with or without lymph node 
dissection (n = 19 and n = 8, respectively) or lymph node 
dissection alone (n = 24). Forty-six out of 51 surgically 
patients received adjuvant treatment, that is, concurrent 
chemoradiotherapy (n = 30) or radiotherapy alone 
(n = 16). Clinical data and treatment details are presented 
in Table 1. For all patients, treatment decisions were 
discussed in a multidisciplinary meeting consisting of 
dedicated head and neck surgeons, medical and radiation 
oncologists, radiologists and pathologists. 
HPV status
HPV status was determined on FFPE material by 
high-risk HPV in situ hybridization (ISH) using the Inform 
HPV III Family B probe (Ventana Medical Systems) on 
a BenchMark XT automated stainer (Ventana Medical 
Systems) under ISO15189:2012 accreditation. The probe 
cocktail detects HPV types 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58 and 66. The high-risk HPV ISH test was 
considered positive if a discrete, blue colored, precipitated 
reaction product within the TCs was observed.
Immunohistochemistry 
Immunohistochemistry for PD-L1 and TILs 
subtyping was performed using the BenchMark XT 
instrument (Ventana Medical Systems inc., Arizona, 
USA). Staining of CD3, CD8 and FoxP3 (DAKO, 
Glostrup, Denmark) was performed on FFPE tissue 
slides of 2µm as previously described [29]. For staining 
of PD-L1, similar antigen retrieval and blocking steps 
were followed by incubation with the anti-PD-L1 primary 
Ab (clone 22C3 diluted 1:100 [Agilent-DAKO, United 
States] and clone SP142 ready-to-use [Roche, Basel, 
Switzerland]) and DAB detection using the Ultraview kit 
(Ventana) and the optiview kit (Ventana), respectively, 
according to the instructions of the manufacturer. Slides 
were counterstained with hematoxylin.
Scoring of the tumor samples
First, a hematoxylin-eosin slide was evaluated 
to confirm the presence of invasive squamous cell 
carcinoma, to determine the grade of tumor differentiation 
and/or define basaloid subtype. The infiltration of TILs 
in tumor stroma was scored semi-quantitatively with 
a 4-tiered scale (1+ to 4+) as previously described 
[29, 30]. Representative scoring for stromal TILs is given 
in Supplementary Figure 2. 
Elaborate evaluation of the immune infiltrate in 
the stromal compartment (i.e. lymphocytes within the 
intertumoral stroma), was done semi-quantitatively by 
scoring for CD3+, CD8+ and FoxP3+ T cell count. For the 
subtyping of the immune infiltrate, three representative 
fields were selected and scored using a similar 4-tiered 
semi-quantitative method as for TIL scoring (1+ to 4+) 
[29, 30] (Supplementary Figure 2). The mean of the separate 
scores from each of the 3 fields was calculated as final 
score, ranging from 1+ to 4+. Necrotic or ulcerated areas 
were excluded from evaluation. Criteria to classify samples 
as ‘impossible to evaluate (ITE)’ were the following: 1) 
(virtually) no tumor stroma present, 2) presence of only a 
Figure 3: Representative immunohistochemical staining for PD-L1 (x200). PD-L1 expression was determined on TCs. Staining 
patterns for SP142 PD-L1 were: IHC 0 (A), IHC 1 (B), IHC 2 (C) and IHC 3 (D). Staining patterns for 22C3 PD-L1 were: IHC 0 (E), IHC 
1 (F), IHC 2 (G) and IHC 3 (H). Staining with SP142 and 22C3 clone was performed on serial sections (2 µm) of the same tumor sample 
for each IHC score respectively.
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minimal invasive carcinoma component and 3) the inability 
to differentiate between the ICs of the pre-existing lymphoid 
tissue of the tonsil and the tumor-associated IC infiltrate.
Subsequently, samples were scored for PD-L1 
expression with both the SP142 clone and the 22C3 clone 
by two independent observers. IHC was scored 0 if < 1% 
of TCs were positive, IHC 1 if ≥ 1% but < 5% of TCs were 
positive, IHC 2 if ≥ 5% but < 10% of TCs were positive or 
IHC 3 if ≥ 10% of TCs were positive (Figure 3) [31]. Mean 
scores between both observers were used in the analyses. 
Cut-off values for PD-L1 positivity on TCs were taken at 
≥ 5% (membranous and/or cytoplasmic) for the SP142 and 
22C3 clone. PD-L1 expression on ICs was evaluated using 
Cell^D imaging software (Olympus Corporation, Tokyo, 
Japan) to ensure objective scoring as the expression of 
PD-L1 on ICs was low. PD-L1 staining was quantified 
in the three same representative fields of intertumoral 
stroma used for scoring of the T cell infiltrate. Scores were 
given as percentages reflecting the ratio of PD-L1 staining 
surface area to the whole surface area of the representative 
field. The final score was determined as the mean of the 
separate scores from the chosen fields. Again, cut-off 
values for PD-L1 positivity on ICs were taken at ≥ 5%.
Statistical analysis
Sample size calculation for a proportional z test of 
the most fitting immune cell marker (CD8+ T cells) has 
shown that 106 patients are needed to achieve a power of 
90% (α = 5%; proportion event group high CD8+ = 0.35; 
proportion event low CD8+ = 0.68; sample ratio high 
CD8+/ low CD8+ = 0.29). Associations between categorical 
variables were determined via Chi-square test. In case of 
2 × 2 contingency tables with 1 or more observed values 
lower than 10, a Fisher’s Exact test was applied. Secondly, 
the HR of immunohistochemical parameters on OS and 
DFS was determined by a log-rank (Mantel–Cox) test. OS 
was calculated from time from diagnosis on biopsy until 
day of death or final follow-up whereas DFS was calculated 
from time of therapy until time of recurrence. For every 
patient who was not seen in clinic for the preceding 12 
months at the point of the survival analysis, the general 
practitioner was contacted to confirm whether the patient 
was still alive. Patients that were lost to follow up at either 
the Ghent University Hospital or the general practitioner 
were censored in the survival analysis (n = 8). Finally, the 
covariate effect of the risk factors on survival analysis, that 
reached a P value lower than 0.1 on univariate log-rank 
test, was determined by means of the Cox proportional 
hazard model (backward method). Samples that were 
classified as ‘ITE’ were not included in the analysis.
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